World's Best Scientists 2026 revealed!
Maria Teresa Petrucci

Maria Teresa Petrucci

Overview

Maria Teresa Petrucci is affiliated with Sapienza University of Rome in Italy. Their research primarily focuses on medicine, with significant contributions to biochemistry, genetics, and molecular biology. Within these domains, their subfields of study include hematology, molecular biology, oncology, genetics, and immunology.

The main areas of research undertaken by Maria Teresa Petrucci revolve around multiple myeloma research and treatments. Other notable topics include protein degradation and inhibitors, peptidase inhibition and analysis, chronic lymphocytic leukemia research, cancer treatment and pharmacology, monoclonal and polyclonal antibodies research, and immune cell function and interaction.

Frequent coauthors collaborating with Maria Teresa Petrucci are:

  • Francesca Fazio
  • Massimo Offidani
  • Renato Zambello
  • Mario Boccadoro
  • Pellegrino Musto

Maria Teresa Petrucci has published regularly in several scientific journals. The most recurrent publication venues include:

  • Blood
  • Cancers
  • Haematologica
  • Blood Cancer Journal
  • HemaSphere

Recent papers authored or coauthored by Maria Teresa Petrucci include the following:

  • Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study, 2020, The Lancet Haematology
  • When killers become thieves: Trogocytosed PD-1 inhibits NK cells in cancer, 2022, Science Advances
  • Impact on NK cell functions of acute versus chronic exposure to extracellular vesicle-associated MICA: Dual role in cancer immunosurveillance, 2022, Journal of Extracellular Vesicles
  • Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial, 2022, The Lancet Haematology
  • Minimal residual disease assessment by multiparameter flow cytometry in transplant-eligible myeloma in the EMN02/HOVON 95 MM trial, 2021, Blood Cancer Journal

Best Publications

  • Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.

    Jesús F. San Miguel;Rudolf Schlag;Nuriet K. Khuageva;Meletios A. Dimopoulos

  • Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group

    Antonio Palumbo;Hervé Avet-Loiseau;Stefania Oliva;Henk M. Lokhorst

  • Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study

    Michele Cavo;Paola Tacchetti;Francesca Patriarca;Maria Teresa Petrucci

  • Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial

    Antonio Palumbo;Sara Bringhen;Tommaso Caravita;Emanuela Merla

  • Continuous Lenalidomide Treatment for Newly Diagnosed Multiple Myeloma

    Antonio Palumbo;Roman Hajek;Michel Delforge;Martin Kropff

  • Autologous transplantation and maintenance therapy in multiple myeloma

    Antonio Palumbo;Federica Cavallo;Francesco Di Raimondo

  • Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis.

    Philip L. McCarthy;Sarah A. Holstein;Maria Teresa Petrucci;Paul G. Richardson

  • Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders

    Andy C Rawstron;Alberto Orfao;Meral Beksac;Ludmila Bezdickova

  • ATM-ATR–dependent up-regulation of DNAM-1 and NKG2D ligands on multiple myeloma cells by therapeutic agents results in enhanced NK-cell susceptibility and is associated with a senescent phenotype

    Alessandra Soriani;Alessandra Zingoni;Cristina Cerboni;Maria Luisa Iannitto

  • Bortezomib-Melphalan-Prednisone-Thalidomide Followed by Maintenance With Bortezomib-Thalidomide Compared With Bortezomib-Melphalan-Prednisone for Initial Treatment of Multiple Myeloma: A Randomized Controlled Trial

    Antonio Palumbo;Sara Bringhen;Davide Rossi;Maide Cavalli

  • Bortezomib Plus Melphalan and Prednisone Compared With Melphalan and Prednisone in Previously Untreated Multiple Myeloma: Updated Follow-Up and Impact of Subsequent Therapy in the Phase III VISTA Trial

    Maria-Victoria Mateos;Paul G. Richardson;Rudolf Schlag;Nuriet K. Khuageva

  • Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma.

    M A Dimopoulos;C Chen;A Spencer;R Niesvizky

  • Maintenance treatment with recombinant interferon alfa-2b in patients with multiple myeloma responding to conventional induction chemotherapy.

    Mandelli F;Avvisati G;Amadori S;Boccadoro M

  • Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma

    Michele Cavo;Lucia Pantani;Maria Teresa Petrucci;Francesca Patriarca

  • Melphalan, Prednisone, and Lenalidomide Treatment for Newly Diagnosed Myeloma: A Report From the GIMEMA—Italian Multiple Myeloma Network

    Antonio Palumbo;Patrizia Falco;Paolo Corradini;Antonietta Falcone

  • Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: results of a randomized controlled trial

    Antonio Palumbo;Sara Bringhen;Maria Teresa Petrucci;Pellegrino Musto

  • Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial.

    Stefania Oliva;Maria Teresa Petrucci;Concetta Conticello

  • Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study

    Michele Cavo;Meral Beksac;Lucia Pantani

  • Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients

    Alessandra Larocca;Pierre Wijermans;Federica Cavallo

  • Persistent Overall Survival Benefit and No Increased Risk of Second Malignancies With Bortezomib-Melphalan-Prednisone Versus Melphalan-Prednisone in Patients With Previously Untreated Multiple Myeloma

    Jesús F. San Miguel;Rudolf Schlag;Nuriet K. Khuageva;Meletios A. Dimopoulos

Frequent Co-Authors

Antonio Palumbo
Antonio Palumbo University of Turin
Mario Boccadoro
Mario Boccadoro University of Turin
Pellegrino Musto
Pellegrino Musto University of Bari Aldo Moro
Michele Cavo
Michele Cavo University of Bologna
Francesco Di Raimondo
Francesco Di Raimondo University of Catania
Paolo Corradini
Paolo Corradini University of Milan
Robin Foà
Robin Foà Sapienza University of Rome
Franco Mandelli
Franco Mandelli Sapienza University of Rome
Pieter Sonneveld
Pieter Sonneveld Erasmus University Rotterdam
Meletios A. Dimopoulos
Meletios A. Dimopoulos National and Kapodistrian University of Athens

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Pursuing Medicine in the USA opens doors to a wide range of online healthcare degrees and flexible career pathways. For registered nurses wanting to advance quickly, rn to np programs offer a direct route to becoming a nurse practitioner without having to start from scratch.

Alternatively, those interested in wellness and dietetics may choose a nutritionist online degree, ideal for building expertise in nutrition science and promoting community health.

Healthcare professionals aiming for leadership roles should consider top cahme accredited mha programs to gain essential management skills and enhance their impact in healthcare organizations.

For busy RNs seeking degree advancement with minimal onsite commitments, there are many online rn to bsn programs without clinical requirements that let you upgrade your credentials while maintaining your work schedule.

Exploring these online degree options can help you align your education with your career ambitions and adapt to the ever-changing landscape of healthcare.

Best Scientists Citing Maria Teresa Petrucci

Trending Scientists

Recently Published Articles